Despite uncertainty surrounding the future of the conflict in the Middle East and Iran’s comments initially rejecting a ceasefire proposal—calling instead for a full end to the conflict and a halt to attacks—European equity indices are moving higher. Germany’s DAX is up 1.5%, with DE40 futures rising above 23,200 points. The UK’s FTSE and France’s CAC 40 are also gaining close to 1.3%, while Poland’s WIG20 is leading the region with gains exceeding 2%.
- Comments from Christine Lagarde, President of the European Central Bank, suggest that the bank is not yet ready to act in either direction and will need time to assess the situation. For the ECB, the key factor will be the extent to which higher energy prices translate into the cost of goods and services, an effect that rem
- UK inflation data came in slightly above expectations, with CPI rising to 3.2% year-on-year versus 3.1% forecast, while producer price indices (PPI) declined more than anticipated. In Germany, the Ifo business climate index surprised to the upside at 86.4 compared to expectations of 86.2, though slightly below the previous reading of 86.7. EUR/USD is slipping to 1.158 today, while the USD index (USDIDX) is rising to 99.2 after falling from around 100.
- US import prices came in up 1,3% vs 0,6% exp. and 0,2% previously while export prices rise 1,6% vs 0,6% exp. and 0,6% previously. The current account came in at -$190 billion vs -$208 bilion exp. and -$226 billion previously. Silver is up almost 1% today rising to $72 per ounce while gold surges almost 1,4% exceeding $4550 per ounce.
Analyst upgrades in focus
-
Croda was upgraded to overweight from equal-weight at Morgan Stanley, making it the second bank to lift its rating on the stock this week. Analysts pointed to the UK chemicals group’s pricing power relative to peers.
-
Roche was upgraded to buy at Intron Health, with the recent selloff seen as excessive and upcoming catalysts viewed as supportive for the investment case.
- Novonesis was double-upgraded to buy at Citi. Citi said the Danish enzymes and biopharma ingredients company’s recent valuation reset now offers a more attractive entry point.
Sector calls: oil and chemicals
-
Morgan Stanley said the oil market is unlikely to be viewed in the same way as before the latest Middle East conflict. The bank upgraded the sector view to attractive and revised its order of preference.
- JPMorgan said the European chemicals sector could see material near-term earnings upside from Middle East-related developments, although the scale and duration would depend on how long disruptions last and how demand elasticity evolves.
Main analysts upgrades / downgrades
- BP raised to overweight at Morgan Stanley.
- Croda raised to overweight at Morgan Stanley; target price 3,350 pence.
- Diageo raised to neutral at BNP Paribas; target price 1,450 pence.
- Equinor raised to equal-weight at Morgan Stanley; target price 388 kroner.
- Evli raised to buy at Inderes; target price 25 euros.
- Lanxess raised to overweight at JPMorgan; target price 18 euros.
- Novonesis raised to buy at Citi; target price 415 kroner.
- Prosus raised to overweight at Morgan Stanley; target price 51 euros.
- Repsol raised to overweight at Morgan Stanley.
- Roche raised to buy at Intron Health.
- SIG Group raised to buy at UBS; target price 15 Swiss francs.
- Stadler Rail raised to neutral at UBS; target price 20 Swiss francs.
- ALK-Abello cut to hold at Nordea.
- Galp cut to equal-weight at Morgan Stanley.
- Shell cut to equal-weight at Morgan Stanley.
New initiations and reinstatements
- Galderma reinstated by Citi; target price 165 Swiss francs.
- Kingspan initiated at outperform by RBC; target price 97 euros.
- ProCredit Holding initiated at buy by Berenberg; target price 15.50 euros.
- Rockwool initiated at perform by RBC; target price 196 kroner.
- Talanx initiated at overweight by JPMorgan; target price 125 euros.
- Vicore Pharma initiated at buy by Guggenheim; target price 38 kronor.
DE40 (D1 interval)
Source: xStation5
Rivian - Partnership with Uber and the R2. Is it a "Tesla killer"?
BREAKING: US Oil Inventories Surge Again. Oil WTI stable above $88
US Open: Iran rejects Trump’s peace plan as S&P 500 remains resilient
OpenAI shuts down “Sora” - What does it mean for the markets?
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
